SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
CANTON, Mass., March 28, 2017 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present at the 16th Annual Needham Healthcare Conference in New York City. The presentation will take place at 10:40 a.m. ET on Wednesday, April 5, 2017 at the Westin New York Grand Central Hotel.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact: Alex Dasalla [email protected]
